Torrent Pharmaceuticals has received a communication from the US Food & Drug Administration (USFDA) classifying the inspection conducted at its Indrad facility in April, 2019 as Official Action Initiated (OAI).
The Company already had submitted its initial response to USFDA and commitments given in response to Form 483 observations have been fulfilled. The Company is sending further updates over receiving of this OAI letter.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.